Bio News
Met all primary endpoints in the phase 3 ACACIA-HCM trial An indication in which rival BMS failed; expected to become the first treatment
Cytokinetics’ cardiac disease treatment Myqorzo (aficamten) met all primary endpoints at week 36 in a phase 3 trial for nonobstructive hypertrophic cardiomyopathy (nHCM), achieving statistical significance. The trial used patient-reported outcomes measured by the KCCQ and improvement in peak exercise capacity as its primary endpoints, while BMS’ competing drug Camzyos failed in a trial for the same indication. With this success, Cytokinetics aims to secure approval for the first treatment for nHCM, double the patient population and promptly begin approval discussions with the FDA.
BIOBOOK TEAM
biobookmedia@biobook.co.krMerck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
Ministry of Trade, Industry and Energy signs agreement to promote biotech and medical devices in Gangwon; site visit set for the 14th
RDA develops technology to produce anti-inflammatory exosomes for pets and files patent application
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
